

Multi-modality Imaging in Pulmonary Arterial Hypertension : Focusing the role of CMR

Hyuk-Jae Chang, MD

Division of Cardiology

Severance Cardiovascular Hospital
Yonsei University Health System

Echocardiography

Pivotal Roles in PAH

- Not confirm, but screen the presence of PH in suspected subjects
- R/O 2ndary etiologies
- FU and monitoring the treatments

Accuracy of Doppler Echocardiography in Hemodynamic Assessment of Pulmonary Hypertension

modified Bernoulli Equation

$$\text{PASP} = 4 \text{ (TR velocity)}^2 + \text{RAP}$$

J Am Coll Cardiol 1985


*establishing good correlation does not imply that
one test is an accurate substitute for another...*

PASP

(Am J Respir Crit Care Med 2009)

Doppler echocardiography was inaccurate in 28% of cases.


(Difference grater than ± 20 mm Hg)



$$\text{PASP} = 4 \ (\text{TR velocity})^2 + \underline{\text{RAP}}$$

RAP

(Am J Respir Crit Care Med 2009)




Pts with Emphysema

DE was inaccurate in about 1/3 of cases.
(Difference greater than $\pm 10\text{mm Hg}$)

PASP


Pearson correlation = 0.23
(95% CI: 0.001-0.44)



(Eur Respir J 2007)

Pts with Advanced Lung Disease

DE was inaccurate in 48% of cases.
(Difference greater than $\pm 10\text{mm Hg}$)



(Am J Respir Crit Care Med 2007)

Contents

- **Emerging role of CMR in PAH: Merit of CMR**
- **Importance and Measurement
of RV function in PAH: Role of CMR**
- **Severance PAH clinic Data**

Merit of CMR


#1. Omni-plane

Clinical indications for CMR : ESC Consensus Report

Although CMR is analogue to echocardiography,
major advantage is that it can be conducted
in any orientation or plane.

Pennell et al. Eur Hear J 2004


Hemodynamic Assessment in PAH



Nogami et al. J Magn Resonance Imaging 2009

#2. Excellent tissue-contrast


CMR Inter-study variability: RV





CV (%)	Normal	CHF	LVH
EDV	4.2 (2.9/ <u>5.5</u>)	7.8 (3.1)	6.2 (4.9)
ESV	8.1 (6.5/ <u>17.5</u>)	14.5 (4.4)	18.1 (9.2)
SVI	4.3 (3.9/ <u>10.7</u>)	7.5 (5.7)	10.8 (5.6)
EF	4.3 (2.4/ <u>8.6</u>)	10.4 (7.3)	10.0 (3.7)
RVMI	7.8 (2.8/ <u>11.6</u>)	9.0 (4.8)	9.4 (3.9)

Grothues, et al. Am Heart J 2004 (2002)

#3. Delayed hyperenhancement




delay contrast
enhancement




Blyth et al. Eur Heart J 2005

#4. PA distensibility



causing further stiffening and shear stress abnormalities and establishing a positive feedback cycle of disease progression.

Jardim et al. Eur Respir J 2007




Sanz et al. JACC CV imaging 2009


#5. PAH & embolism with MRA

(CHEST 2001; 120:1556–1561)

Methods: Fifty patients (21 women; mean [\pm SD] age, 52 ± 16 years) were examined with gadolinium-enhanced PMRA for the evaluation of pulmonary artery (PA) disease. The diagnosis of PAH (ie, systolic PA pressure of > 35 mm Hg) was determined by Doppler echocardiography. The criteria for the diagnosis of chronic PAH by PMRA were dilated central PAs (diameter > 28 mm) and abnormal proximal-to-distal tapering of the PAs. The diagnostic criterion for acute and chronic PE was the presence of an intravascular filling defect.



Lung Perfusion MRI: PTE



Fink et al. Fortschr Roentgenstr 2004

ACCF/ACR/AHA/NASCI/SCMR 2010

Expert Consensus on CMR

**No guidelines or appropriate use criteria
highlighting the utility of CMR for assessment
of pulmonary artery diseases exclusive of
congenital heart disease.**

Hundley et al. Circulation 2010



Contents

- Emerging role of CMR in PAH
- Importance and Measurement of RV function in PAH: Role of CMR
- Severance PAH clinic Data

Predictors of Survival

-PPH (N=178), NYHA III/IV-

Variables	HR (95% CI)	P-value
Age		NS
Gender		NS
Hx. of Syncope		NS
Hx. of RHF	2.19 (1.31-3.64)	0.003
NYHA IV vs. III	2.24 (1.34-3.73)	0.002
6MWD (<250m)	2.20 (1.31-3.69)	0.003
mRAP (>12mmHg)	2.74 (1.58-4.75)	0.0003
mPAP (<65mmHg)	1.72 (1.04-2.86)	0.036
Cardiac Index		NS
TPR		NS
SvO2 (<55%)		NS

Stibon et al. JACC 2002

Parameters in evaluation of RV function



Functional Parameters	Clinical Utility	Load Dependence*
RVEF, %	Clinical validation, wide acceptance Prognostic value in cardiopulmonary disorders ⁹	+++
RVFAC, %	Good correlation with RVEF Prognostic value in MI and bypass surgery ⁴⁸	+++
TAPSE, mm	Simple measure not limited by endocardial border recognition: Good correlation with RVEF	+++
Sm annular, cm/s	Good sensitivity and specificity for RVEF <50% ⁶³	+++
Strain	Correlates with stroke volume ^{69,70}	+++
Strain rate, s ⁻¹	Correlates with contractility ^{69,70}	++
Maximal RV elastance, mm Hg/mL	Most reliable index of contractility ⁹	+

Haddad et al Circulation 2008

RV performance: MRI analysis of RV Pressure-Volume loop





Balloon-tipped
catheter in R V



Kuehne et al. Circulation 2004


RV performance: MRI analysis of RV Pressure-Volume loop



Kuehne et al. Circulation 2004

Other application of PC-CMR in PAH

: AT, ET and AV



Sanz et al Radiology 2007

Contents

- Emerging role of CMR in PAH
- Importance and
Measurement of RV function in PAH
- Severance PAH clinic Data

Study Aims

- To validate the correlation of CMR-derived index with RV hemodynamics in PAH
- To compare it to clinical performance in patients with PAH



Study Design

- **Prospective, Mar2009-Jul 2010**
- **In Severance PAH Clinic**
- **Total 30 among 50 consecutive patients**
- **Work-up**
 - **Pre-Tx: Lab, TTE, RHC, CMR and 6MWT**
 - **Post-Tx: Lab, TTE and 6MWT within 3-6 months**

Clinical Characteristics

	Patients (N=30)
Age	45±14
Male (%)	9 (30%)
BSA (Kg/m ²)	1.64±0.22
Idiopathic PAH (%)	15 (50%)
6MWD(m)	370±103
mRAP (mmHg)	14.33±14.62
mPAP (mmHg)	50.96± 23.1
Stroke Volume (ml)	57.96 ± 25.32
Cardiac Output (L/min)	4.44 ± 1.63
PVR (Wood Unit)	10.33 ± 6.52


DHE to mPAP and RV function





Multivariate Regression of 6MWD

Variable	OR (95%CI)	P value
Age	0.94(0.79-1.12)	0.50
Functional Class (I-IV)	0.74(0.82-1.28)	0.88
mRAP (mmHg)	1(0.92-1.23)	0.40
mPAP (mmHg)	0.98(0.86-1.12)	0.83
PVR (wood unit)	1(0.85-1.39)	0.49
PA Distensibility (%)	1.6(1.02-2.48)	0.03*
RVEF (%)	1(0.82-1.28)	0.88

6MWD and PA distensibility



CMR-derived RVOTacc (m/s^2)



Comparison of different imaging modalities in PAH

Metric	CMR	Echo-TTE	Echo-TEE	x-ray catheterisation	Nuclear
RV volumes (ml)	+++	++	+++	+	+
Ejection fraction (%)	+++	+	+	+	-
RV mass (g)	+++	+	+	-	-
RV pressure (mmHg)	+	++	++	+++	-
RV remodelling including septal curvature	+++	+	+	-	-
RA size/volume	+++	+	+	-	-
Tricuspid regurgitation	++	+++	+++	-	-
Pulmonary artery/branch (mm)	+++	+	+	+	-
Pulmonary artery compliance (mm/mmHg)	+++	+	+	+	-
Pulmonary artery flow (ml/beat)	+++	+	+	+++	-
Qp:Qs (shunt)	+++	+	+	+++	-
Pericardial effusion	+++	++	++	-	-

CMR is the most suitable to provide the information of PAH-related metrics in the most of cases.

Benza, J Am Coll Cardiol 2008




MRI One-Stop Shop for the Comprehensive Assessment of PAH

Anatomy
Function

Flow

Angiogram

Perfusion



Estimated average costs of CMR and other cardiac imaging procedures

Pennell et al. Eur Hear J 2004

	Average Cost	Cost Range
Echocardiography	1	1
CT	3.13	±1.39
SPECT	3.27	±2.88
CMR	5.51	±3.51
RHC and LHC	19.96	±13.55

Overall incidence of claustrophobia leading to cancellation of postoperative MRI was 14%.

Katznelson et al. Neuropsychiatr Dis Treat 2008

Conclusions

CMR may provide more accurate and broad variety of information than echocardiography for the non-invasive evaluation of RV and PA structure and function that is integral to PH... go a long way to replace echocardiography but is a complementary tool as a reference standard.